420 related articles for article (PubMed ID: 38254718)
1. Current Technologies Unraveling the Significance of Post-Translational Modifications (PTMs) as Crucial Players in Neurodegeneration.
Zafar S; Fatima SI; Schmitz M; Zerr I
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254718
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Role of Aberrant Protein Post-Translational Modification in the Pathology of Neurodegeneration.
Shafi S; Singh A; Gupta P; Chawla PA; Fayaz F; Sharma A; Pottoo FH
CNS Neurol Disord Drug Targets; 2021; 20(1):54-67. PubMed ID: 32885763
[TBL] [Abstract][Full Text] [Related]
3. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
He S; Wang F; Yung KKL; Zhang S; Qu S
ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
[TBL] [Abstract][Full Text] [Related]
4. Targeting α-synuclein post-translational modifications in Parkinson's disease.
Canever JB; Soares ES; de Avelar NCP; Cimarosti HI
Behav Brain Res; 2023 Feb; 439():114204. PubMed ID: 36372243
[TBL] [Abstract][Full Text] [Related]
5. Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation.
Alquezar C; Arya S; Kao AW
Front Neurol; 2020; 11():595532. PubMed ID: 33488497
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders.
Ramazi S; Allahverdi A; Zahiri J
J Biosci; 2020; 45():. PubMed ID: 33184251
[TBL] [Abstract][Full Text] [Related]
7. The Role of Post-Translational Modifications on the Structure and Function of Tau Protein.
Ye H; Han Y; Li P; Su Z; Huang Y
J Mol Neurosci; 2022 Aug; 72(8):1557-1571. PubMed ID: 35325356
[TBL] [Abstract][Full Text] [Related]
8. Post-translational modifications: Regulators of neurodegenerative proteinopathies.
Gupta R; Sahu M; Srivastava D; Tiwari S; Ambasta RK; Kumar P
Ageing Res Rev; 2021 Jul; 68():101336. PubMed ID: 33775891
[TBL] [Abstract][Full Text] [Related]
9. A validated antibody panel for the characterization of tau post-translational modifications.
Ercan E; Eid S; Weber C; Kowalski A; Bichmann M; Behrendt A; Matthes F; Krauss S; Reinhardt P; Fulle S; Ehrnhoefer DE
Mol Neurodegener; 2017 Nov; 12(1):87. PubMed ID: 29157277
[TBL] [Abstract][Full Text] [Related]
10. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease.
Balmik AA; Chinnathambi S
Cell Commun Signal; 2021 May; 19(1):51. PubMed ID: 33962636
[TBL] [Abstract][Full Text] [Related]
11. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
12. Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review.
Schaffert LN; Carter WG
Brain Sci; 2020 Apr; 10(4):. PubMed ID: 32290481
[TBL] [Abstract][Full Text] [Related]
13. Triaging between post-translational modification of cell cycle regulators and their therapeutics in neurodegenerative diseases.
Rani N; Sahu M; Ambasta RK; Kumar P
Ageing Res Rev; 2024 Feb; 94():102174. PubMed ID: 38135008
[TBL] [Abstract][Full Text] [Related]
14. Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology.
Kalyaanamoorthy S; Opare SK; Xu X; Ganesan A; Rao PPN
Curr Alzheimer Res; 2024 Apr; ():. PubMed ID: 38623984
[TBL] [Abstract][Full Text] [Related]
15. The Involvement of Post-Translational Modifications in Regulating the Development and Progression of Alzheimer's Disease.
Guan PP; Wang P
Mol Neurobiol; 2023 Jul; 60(7):3617-3632. PubMed ID: 36877359
[TBL] [Abstract][Full Text] [Related]
16. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
Thomas SN; Yang AJ
Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
[TBL] [Abstract][Full Text] [Related]
17. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
Haj-Yahya M; Lashuel HA
J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
[TBL] [Abstract][Full Text] [Related]
18. The Involvement of Post-Translational Modifications in Alzheimer's Disease.
Marcelli S; Corbo M; Iannuzzi F; Negri L; Blandini F; Nistico R; Feligioni M
Curr Alzheimer Res; 2018 Feb; 15(4):313-335. PubMed ID: 28474569
[TBL] [Abstract][Full Text] [Related]
19. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
Brembati V; Faustini G; Longhena F; Bellucci A
Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556
[TBL] [Abstract][Full Text] [Related]
20. The role of post-translational modifications in cardiac hypertrophy.
Yan K; Wang K; Li P
J Cell Mol Med; 2019 Jun; 23(6):3795-3807. PubMed ID: 30950211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
